Silence Therapeutics (SLN) AI Stock Analysis

• Market Cap: $230.97M
• Dividend Yield: N/A
• Average Volume (3M): 62.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -40.10%
• EPS Growth: -16.60%
• Country: US
• Employees: 116
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 47,233,948
• 10 Day Avg. Volume: 78,449
• 30 Day Avg. Volume: 62,444
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.69
• Enterprise Value/Revenue: 6.18
• Enterprise Value/Gross Profit: 7.50
• Enterprise Value/Ebitda: -2.83
• 1Y Price Target: $50.00
• Price Target Upside: 922.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 49 Neutral
• Price Target: $5.50 ▲(12.47% Upside)

Silence Therapeutics faces significant financial challenges, with negative profitability and concerning balance sheet metrics. Technical indicators suggest neutral to bearish momentum. Valuation is weak due to negative earnings. However, recent corporate governance improvements provide some positive outlook.

Positive Factors

Corporate Governance

The successful passing of key resolutions at the AGM, including director reappointments and auditor ratification, indicates a strategic focus on governance and financial oversight, which can enhance operational stability and stakeholder confidence over the long term.

Cash Reserves

Substantial cash reserves provide Silence Therapeutics with a buffer to support ongoing operations and strategic initiatives, offering financial flexibility to weather challenges and invest in growth opportunities, which is crucial for long-term sustainability.

Financing Flexibility

The ability to secure significant financing supports operational needs despite negative cash flow, providing Silence Therapeutics with the flexibility to continue funding its R&D and strategic initiatives, which is vital for long-term growth and innovation.

Negative Factors

Profitability Challenges

Persistent profitability challenges, highlighted by negative EBIT and net income margins, indicate ongoing difficulties in achieving cost efficiency or revenue growth, which can hinder long-term financial health and investor confidence.

Negative Equity

Negative stockholders' equity signals financial instability, posing risks to Silence Therapeutics' ability to raise capital and invest in growth, which could impact long-term viability and strategic execution.

Cash Flow Challenges

Consistently negative free cash flow indicates ongoing operational cash challenges, which can limit Silence Therapeutics' ability to fund R&D and strategic initiatives, potentially impacting long-term growth and innovation capabilities.

Silence Therapeutics Business Overview & Revenue Model

Company Description

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

How the Company Makes Money

Silence Therapeutics generates revenue primarily through collaboration agreements and partnerships with pharmaceutical companies. These collaborations typically involve upfront payments, milestone payments tied to the progression of drug candidates through clinical development, and royalties on future product sales. The company also seeks funding through grants and research contracts that support its therapeutic development programs. Additionally, advancements in its pipeline and successful clinical trial outcomes can significantly enhance its revenue potential through licensing agreements or partnerships for commercialization.

Silence Therapeutics Financial Statement Overview

Summary

Silence Therapeutics shows revenue growth but struggles with profitability, negative equity, and cash flow challenges. The financial instability is a significant concern, requiring strategic improvements in cost management and financial planning.

Income Statement

Silence Therapeutics has demonstrated significant revenue growth over the years, with a notable increase from 2023 to 2024. However, the company continues to face challenges with profitability, as evidenced by negative EBIT and net income margins. The consistent negative profit margins highlight a need for enhanced cost management or increased revenue to achieve profitability.

Balance Sheet

The company's balance sheet reveals a concerning negative stockholders' equity as of 2024, indicating financial instability. The debt-to-equity ratio is not favorable due to the negative equity, and although the company maintains substantial cash reserves, the high liabilities present a risk. Improving equity and managing liabilities are critical for financial health.

Cash Flow

Silence Therapeutics has managed significant financing cash flow, which supports its operations despite negative operating cash flow. The free cash flow has been consistently negative, reflecting ongoing cash challenges. However, the company's ability to secure financing offers some operational flexibility. Improving free cash flow is essential for sustainable growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	25.84M	43.26M	25.38M	17.50M	12.41M	5.48M
Gross Profit	21.32M	31.45M	15.06M	6.62M	4.96M	1.72M
EBITDA	-56.55M	-48.99M	-49.78M	-47.88M	-45.42M	-35.53M
Net Income	-68.72M	-45.31M	-43.27M	-40.49M	-39.41M	-32.55M
Balance Sheet
Total Assets	165.23M	202.63M	93.82M	107.50M	96.19M	85.97M
Cash, Cash Equivalents and Short-Term Investments	114.16M	147.33M	54.03M	71.14M	73.54M	37.45M
Total Debt	0.00	117.00K	272.00K	446.00K	137.00K	341.00K
Total Liabilities	71.08M	68.61M	76.77M	85.43M	87.67M	76.91M
Stockholders Equity	94.16M	134.02M	17.05M	22.07M	8.53M	9.06M
Cash Flow
Free Cash Flow	-78.77M	-67.85M	-39.40M	-45.90M	5.47M	-11.29M
Operating Cash Flow	-78.61M	-67.64M	-39.35M	-45.46M	6.81M	-10.78M
Investing Cash Flow	-6.66M	-21.97M	16.43M	-16.54M	8.68M	9.62M
Financing Cash Flow	25.86M	142.09M	25.16M	43.05M	30.71M	15.43M

Silence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Negative. The current price of 4.89 is below the 20-day moving average (MA) of 5.03, below the 50-day MA of 5.54, and below the 200-day MA of 5.14, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 44.72 is Neutral, neither overbought nor oversold. The STOCH value of 44.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLN.

Silence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADCT	54 Neutral	384.75M	-2.18	77.89%	―	15.73%	38.73%
FDMT	52 Neutral	308.24M	-1.78	-31.51%	―	0.00%	0.00%
SLN	49 Neutral	$230.97M	―	-99.23%	―	-40.10%	-16.60%
KRRO	45 Neutral	338.54M	-3.70	0.00%	―	0.00%	61.73%
KLRS	28 Underperform	75.99M	-0.60	0.00%	―	0.00%	73.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Silence Therapeutics Corporate Events

Michael Davidson Resigns from Silence Therapeutics Board

On August 11, 2025, Michael Davidson resigned from the board of directors of Silence Therapeutics plc to focus on his role as CEO of NewAmsterdam Pharma Company N.V. His departure was not due to any disagreements with the company. The board expressed gratitude for his contributions and reduced its size from five to four directors, appointing Iain Ross to fill the vacancy on the Audit and Risk Committee.

Silence Therapeutics Passes Key Resolutions at AGM

On June 26, 2025, Silence Therapeutics held its Annual General Meeting where all thirteen proposed resolutions were passed. Key decisions included the reappointment of directors, approval of executive compensation on an annual basis, and the ratification of PricewaterhouseCoopers LLP as auditors. These resolutions reflect the company’s strategic focus on governance and financial oversight, potentially strengthening its operational stability and stakeholder confidence.